Last reviewed · How we verify

NCT06839300

The International Spinal Cord Injury Blood Biomarker Longitudinal Evaluation (I-SCRIBBLE) Study

Recruiting now Last updated 3 March 2026
What this trial tests

trial in Spinal Cord Injury in 260 participants. Currently enrolling.

Timeline
9 February 2026
Primary endpoint
1 December 2029
1 December 2029

Quick facts

Lead sponsorAO Foundation, AO Spine
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment260
Start date9 February 2026
Primary completion1 December 2029
Estimated completion1 December 2029
Sites8 locations across New Zealand, Chile, United Kingdom, Germany, Australia, United States, Brazil, India

Conditions studied

Sponsor

AO Foundation, AO Spine

Who can join

19 and older, any sex, with Spinal Cord Injury. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To determine the accuracy of serum NF-L and GFAP levels (ie the biomarkers) at different time points postinjury for predicting the severity of neurologic impairment at 6 months postinjury as either motor complete (AIS grade A/B) or motor incomplete (AIS grade C/D) a group of patients who suffer traumatic spinal fracture and/or dislocation of the spinal column but without neurologic injury will be enrolled as non-SCI spine trauma control participants.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Spinal Cord Injury

Currently open trials in the same condition.

Other AO Foundation, AO Spine trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06839300.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing